Anika Therapeutics, Inc. ANIK
We take great care to ensure that the data presented and summarized in this overview for Anika Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANIK
View all-
Trigran Investments, Inc.2.07MShares$53.2 Million5.1% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$40 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX810KShares$20.8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA774KShares$19.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY702KShares$18 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny560KShares$14.4 Million0.02% of portfolio
-
Boothbay Fund Management, LLC New York, NY502KShares$12.9 Million0.31% of portfolio
-
Acadian Asset Management LLC Boston, MA421KShares$10.8 Million0.04% of portfolio
-
Capital Management Corp364KShares$9.34 Million1.94% of portfolio
-
Geode Capital Management, LLC Boston, MA329KShares$8.44 Million0.0% of portfolio
Latest Institutional Activity in ANIK
Top Purchases
Top Sells
About ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Transactions at ANIK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2024
|
Michael L Levitz EVP, CFO, Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,638
-4.26%
|
$140,950
$25.54 P/Share
|
|
Mar 11
2024
|
Michael L Levitz EVP, CFO, Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,201
+12.62%
|
-
|
|
Mar 11
2024
|
Anne Nunes SVP, Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,720
-7.9%
|
$43,000
$25.61 P/Share
|
|
Mar 11
2024
|
Anne Nunes SVP, Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,856
+21.06%
|
-
|
|
Mar 11
2024
|
David Colleran EVP, General Counsel, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
4,936
-5.41%
|
$123,400
$25.54 P/Share
|
|
Mar 11
2024
|
David Colleran EVP, General Counsel, Corp Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
16,809
+15.52%
|
-
|
|
Mar 11
2024
|
Cheryl R Blanchard President, CEO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
27,980
-6.22%
|
$699,500
$25.54 P/Share
|
|
Mar 11
2024
|
Cheryl R Blanchard President, CEO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
64,480
+12.54%
|
-
|
|
Oct 01
2023
|
Anne Nunes SVP, Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
732
-12.66%
|
$13,176
$18.63 P/Share
|
|
Oct 01
2023
|
Anne Nunes SVP, Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,491
+30.1%
|
-
|
|
Aug 10
2023
|
Michael L Levitz EVP, CFO, Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,133
-3.3%
|
$20,394
$18.58 P/Share
|
|
Aug 10
2023
|
Michael L Levitz EVP, CFO, Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,859
+10.1%
|
-
|
|
Jun 14
2023
|
Sheryl L Conley Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+22.31%
|
-
|
|
Jun 14
2023
|
Gary P Fishetti Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+23.07%
|
-
|
|
Jun 14
2023
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.84%
|
-
|
|
Jun 14
2023
|
Glenn R. Larsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.65%
|
-
|
|
Jun 14
2023
|
Stephen Richard Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+18.88%
|
-
|
|
Jun 14
2023
|
Jeffery S Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.07%
|
-
|
|
Jun 14
2023
|
Susan L N Vogt Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.67%
|
-
|
|
Apr 26
2023
|
Cheryl R Blanchard President, CEO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
10,900
-8.71%
|
$283,400
$26.34 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 45.5K shares |
|---|---|
| Exercise of conversion of derivative security | 113K shares |
| Payment of exercise price or tax liability | 42.1K shares |
|---|